

Shield Therapeutics and Norgine enter into an exclusive license agreement for Feraccru® in Europe, Australia and New Zealand

Torreya advised Shield on the license of Feraccru® in Europe, Australia and New Zealand

London, United Kingdom and Amsterdam, Netherlands, September 19, 2018

Shield Therapeutics, a London based specialty pharmaceutical company, announced it entered into an exclusive licensing agreement with Norgine B.V. for the commercialization of Ferraccru® in Europe, Australia and New Zealand. Ferraccru® is Shield's approved product for the treatment of iron deficiency in adults.

Under the terms of the agreement, Shield will receive an upfront payment of £11 million and up to €54.5 million in development and sales milestones. Shield will also receive tiered royalties ranging from 25% to 40% of net sales of Feraccru®. Shield retains full commercial rights to Feraccru® in all unlicensed countries including the US. Shield also retains full ownership of the global intellectual property rights to Feraccru® including the responsibility for completing an ongoing AEGIS-H2H study. The deal extends Shield's cash runway to continue to develop Feraccru®, as well as pursue further opportunities to out-license.

Torreya served as financial advisor to Shield on this transaction. This transaction reinforces Torreya's strength and leadership position as an advisor to life sciences companies. Torreya has advised on 15 completed strategic and financing transactions in the life sciences industry thus far in 2018.

ABOUT SHIELD THERAPUETICS, PLC:

For more information about Shield, please see: www.shieldtherapeutics.com

ABOUT NORGINE B.V.:

For more information about Norgine, please see: www.norgine.com

Deal Press Release

Torreya Contact

STEPHANIE LÉOUZON

Partner | London Office

stephanie.leouzon@torreya.com | +44 (0) 207.451.4551 | torreya.com



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.